“Metformin Particularly Effective in Those With History of GDM”

Metformin Particularly Effective in Those With History of GDM – check out this article written in Medscape for more information. 

Women with a history of GDM who developed prediabetes that were started on Metformin decreased risk of developing type 2 diabetes by 41% at the 15 year mark. Wow.

 


 

Interested in learning more about women and diabetes? Check out our Online University course:

Level 2 – Women and Diabetes 1.0 CEs – $19.00

Women with diabetes are confronted with a variety of issues that require special attention, education and understanding. This course reviews those special needs while focusing on Gestational Diabetes and Pre-Existing Diabetes.

 

Canagliflozin Amputation Warning!
The FDA is warning that Canagliflozin puts patients at higher risk of amputation.

Patients at higher risk of amputation include those with a history of prior amputation, peripheral vascular disease, neuropathy, and diabetic foot ulcers. Monitor patients on canagliflozin for any signs of extremity sores, ulcers or pain and discontinue canagliflozin.

The FDA urges health care professionals and patients to report side effects involving canagliflozin and other medicines to the FDA MedWatch program, using the information in the Contact FDA box at the bottom of the page.

This is based on results from two clinical trials – the CANVAS (Canagliflozin Cardiovascular Assessment Study) and CANVAS-R (A Study of the Effects of Canagliflozin on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus) – showed that
leg and foot amputations occurred about twice as often in patients treated with canagliflozin compared to patients treated with placebo, which is an inactive treatment.

Amputations of the toe and middle of the foot were the most common; however, amputations involving the leg, below and above the knee, also occurred. Some patients had more than one amputation, some involving both limbs.

The CANVAS trial showed that over a year’s time, the risk of amputation for patients in the trial were equivalent to:

  • 5.9 out of every 1,000 patients treated with canagliflozin
  • 2.8 out of every 1,000 patients treated with placebo

The CANVAS-R trial showed that over a year’s time, the risk of amputation for patients in the trial were equivalent to:

  • 7.5 out of every 1,000 patients treated with canagliflozin
  • 4.2 out of every 1,000 patients treated with placebo

Upcoming Courses and Events

Upcoming Courses & Events

View Full Calendar

Latest Video

Watch Our Short “How-To” and Product Videos